Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of alfentanil before rocuronium to prevent withdrawal movement
ChiCTR2100045137Phase 4Recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of alfentanil in Withdrawal movement (2 arms), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Time interval for 50% suppression of rocuronium-induced withdrawal movement. Started May 2021; status: recruiting.
02
Drugs
alfentanil
03
Conditions
Withdrawal movement
Beyond the preview
Go deeper on ChiCTR2100045137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045137.